Search Results - Roger von Moos

Refine Results
  1. 1
    Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain

    Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain by Roger von Moos, Luís Costa, Carla Ripamonti, Daniela Niepel, Daniele Santini

    Published 2016
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma

    Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma by Reinhard Dummer, Merlin Guggenheim, AW Arnold, Ralph P. Braun, Roger von Moos

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study

    Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study by Ignace Vergote, Roger von Moos, Luís Manso, Els Van Nieuwenhuysen, Nicole Concin, Cristiana Sessa

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody

    Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody by Roger von Moos, Luís Costa, Eva González‐Suárez, Evangelos Terpos, Daniela Niepel, Jean‐Jacques Body

    Published 2019
    Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer

    Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer by G. Fürstenberger, Roger von Moos, Rudolf Lucas, Beat Thürlimann, H-J Senn, Jürg Hamacher, E-M Boneberg

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland

    A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland by Tämer El Saadany, Judith E. Lupatsch, Michael Mark, Michaela Barbier, Tarun Mehra, Matthias Schwenkglenks, Roger von Moos

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment

    Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment by A Glaus, Ch. Boehme, Beat Thürlimann, Thomas Ruhstaller, S.‐F. Hsu Schmitz, R. Morant, H.-J. Senn, Roger von Moos

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing

    A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing by Klazien Matter‐Walstra, Matthias Schwenkglenks, Stefan Aebi, Konstantin J. Dedes, Joachim Diebold, Mario Pietrini, Dirk Klingbiel, Roger von Moos, Oliver Gautschi

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

    Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours by Gianluca Del Conte, Cristiana Sessa, Roger von Moos, Lucia Viganò, Tiziana Digena, Alberta Locatelli, Elisa Gallerani, Angelica Fasolo, Anna Tessari, Richard Cathomas, Luca Gianni

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study

    Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study by Florian Strasser, Thomas A. Lutz, Micha T. Maeder, B. Thuerlimann, Doug Bueche, M. Tschöp, K. Kaufmann, Birgitte Holst, Michael Brändle, Roger von Moos, Ruth Demmer, T. Cerny

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Encorafenib (Lgx818), an Oral Braf Inhibitor, in Patients (Pts) with Braf V600E Metastatic Colorectal Cancer (Mcrc): Results of Dose Expansion in an Open-Label, Phase 1 Study

    Encorafenib (Lgx818), an Oral Braf Inhibitor, in Patients (Pts) with Braf V600E Metastatic Colorectal Cancer (Mcrc): Results of Dose Expansion in an Open-Label, Phase 1 Study by Carlos Gomez‐Roca, Jean‐Pierre Delord, Caroline Robert, Manuel Hidalgo, Roger von Moos, Ana Arance, Elena Élez, Daniela Michel, Abdelkader Seroutou, Tim Demuth, Josep Tabernero

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer

    Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer by Dieter Koeberle, Roger Burkhard, Roger von Moos, Sun Young Rha, Viviane Hess, F. Heitzmann, Thomas Ruhstaller, L. Terraciano, J. Neuweiler, G. Bieri, C Rust, M. Toepfer

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma

    The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma by Reinhard Dummer, Marco Siano, Robert E. Hunger, Nicole Lindenblatt, Ralph P. Braun, Olivier Michielin, Daniela Mihic‐Probst, Roger von Moos, Yousef Najafi, Matthias Gückenberger, Andreas Arnold

    Published 2016
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  14. 14
    Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma

    Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma by Ying Waeckerle‐Men, Edith Uetz‐von Allmen, M. Fopp, Roger von Moos, Christel Böhme, Hans‐Peter Schmid, Daniel Ackermann, Thomas Cerny, Burkhard Ludewig, Marcus Groettrup, Silke Gillessen

    Published 2006
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MO AIC, a multicenter cluster-randomized phase III study (SAKK 95/06)

    The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MO AIC, a multicenter cluster-ran... by Florian Strasser, David Blum, Roger von Moos, Richard Cathomas, Karin Ribi, Stefan Aebi, Daniel Betticher, Stefanie Hayoz, Dirk Klingbiel, Peter Brauchli, Michael Haefner, Silvia Mauri, S. Kaasa, Dieter Koeberle

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

    Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tu... by David H. Henry, Saroj Vadhan‐Raj, Vera Hirsh, Roger von Moos, Vânia Hungria, Luís Costa, Penella J. Woll, Giorgio V. Scagliotti, Geoffrey Smith, Amy Feng, Susie Jun, Roger Dansey, Howard Yeh

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid

    Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid by Saroj Vadhan‐Raj, Roger von Moos, Lesley Fallowfield, Donald L. Patrick, François Goldwasser, Charles S. Cleeland, David H. Henry, Silvia Novello, Vânia Hungria, Yi Qian, A. Feng, Hong‐Zen Yeh, Karen Chung

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)

    Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAK... by Thomas Ruhstaller, Miklos Pless, Daniel Dietrich, Helmut Kranzbuehler, Roger von Moos, Peter Moosmann, Michael Montemurro, Paul M. Schneider, Daniel Rauch, Oliver Gautschi, Walter Mingrone, Lucas Widmer, Roman Inauen, Peter Brauchli, Viviane Hess

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)

    Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02) by Thomas Ruhstaller, L. Widmer, Jan C. Schuller, A. Roth, Viviane Hess, Walter Mingrone, Roger von Moos, Markus Borner, Bernhard C. Pestalozzi, Sabine Balmer-Majno, Dieter Köberle, L. Terraciano, Armin Schnider, Stephan Bodis, Răzvan Popescu

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)

    First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07) by Roger von Moos, Burkhardt Seifert, Mathew Simcock, Simone M. Goldinger, Silke Gillessen, Adrian F. Ochsenbein, Olivier Michielin, Richard Cathomas, Marc Schläppi, Holger Moch, Peter Schraml, D. Mjhic-Probst, Christoph Mamot, Nicola Schönewolf, Reinhard Dummer

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: